Abstract | The Renaissance Of Psilocybin as The Potential Depression Treatment

Author: Vladyslava Dral

Scientific advisor: Lekhkun G. V. Department of Foreign languages Bukovinian State Medical University

The cruel  punishment with no  running  nose, fractures, rash or fever…  Just  the  longing  for something you are unable to explain… Commonly romanticized and misinterpreted condition, so- called “unholy ghost” of psychiatry, major depression is the constellation of symptoms. An individual might be overwhelmed with inability to feel pleasure, insomnia, appetite loss, slowing in speech etc. When the turmoil of negativity within is no more bearable the one might find substance abuse and self- harm  to be the appealing option to end up with the darkness of soul.

As the matter of fact, depression, the biochemical disorder, with genetic component and early experience influences is the fourth common cause of disability worldwide. The nature of the stated psychiatric pathology being yet obscure, there is the significant controversy in terms of the relevant treatment. What  we currently  witness is that  the  notions once  considered doubtless are being contradicted with the  updates in psychiatric research. Recently  under the  USA federal control  the highly restricted  studies were  conducted to test the  psychedelic  compound – psilocybin  as the potentially efficient depression treatment. The stated substance has the paradoxical history of being isolated by the Swiss chemist Dr. Albert Hoffman in 1957, clinically tested, eventually misused and illegalized and listed as the drug with no therapeutic benefit. After being on pause for decades, the psilocybin clinical research was brought about in 2009 at the University of Arizona.

As 18 clinical trials were performed so far, psilocybin is considered to be the new era in treating depression, as well as the  diverse forms of addiction and migraines . For instance, 80  percent of patients  suffering  from   cancer-related  resistant  depression  or   anxiety  felt   alleviation  for approximately 6 months after taking a single dose of psilocybin. There is the notable contrast with the other  antidepressants taking over two or three months to show effect  frequently with the side effects. Moreover,  the  risk of developing an addiction for the  substance is astoundingly low in comparison with its alternatives as there is no need in increasing the dose. All in all, nothing  is more devastating than  being colourblind and constantly told how colourful and bright the world is. Despite controversy in terms of treatment, by no means do we have the right to neglect the  suffering of those whose  the  mental wounds might  hurt  more  than anything that bleeds.

The complete BIMCO Issue 2019 can be accessed here:

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.